NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.
The Boston-based company announced preclinical data for its novel “G-Protein-Coupled Receptor 119 (GPR119) agonist,” known as DA-1241.
The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective effects compared to either treatment alone.
DA-1241 did not influence liver weight, the company said.
In contrast, semaglutide reduced body weight by approximately 25% and improved hepatomegaly in GAN DIO-MASH mice with or without combination treatment.
There was no additional weight loss in the combination group compared to semaglutide alone.
- DA-1241 and semaglutide monotherapy each improved NAS (≥2-point) in 21% of mice
- Combination treatment led to marked improvements (≥2-point in 80% of mice and ≥1-point in all mice), driven by reduction in steatosis and lobular inflammation scores.
- Combination therapy synergistically promoted quantitative histology for steatosis compared to monotherapies.
- Treatments did not significantly influence quantitative markers of fibrosis (PSR, Col1a1)
- DA-1241 and semaglutide in monotherapy lowered α-SMA levels with further improvement in combination treatment, suggesting additive inhibitory effects on fibrogenesis.
- At the end of treatment, semaglutide reduced body weight by approximately 17% (p < 0.05 vs. vehicle control), while DA-1241 (-2.8%) showed little effect.
- There was no additional weight loss in the combination group (-19%, p < 0.05) compared to semaglutide alone.
- Collagen fiber deposition was prominent in mice treated with vehicle compared to the normal control group.
DA-1241 or semaglutide alone lowered collagen-positive area compared to the vehicle-treated group (17.8%, 17.1% vs. 25.8%, p < 0.05). Their combination therapy elicited a further reduction to 6.05% (p < 0.05) compared with each treatment alone.
Price Action: NRBO shares are down 6.11% at $4.30 at last check Wednesday.
Image: Shutterstock